Literature DB >> 20609196

RHCE*ceCF encodes partial c and partial e but not CELO, an antigen antithetical to Crawford.

Christine Halter Hipsky1, Christine Lomas-Francis, Akiko Fuchisawa, Marion E Reid, Marilyn Moulds, Joann Christensen, Pam Nickle, Sunitha Vege, Connie Westhoff.   

Abstract

BACKGROUND: RH43 (Crawford) is encoded by RHCE*ce with nucleotide changes 48G>C, 697C>G, and 733C>G (RHCE*ceCF). We investigated the Rh antigen expression and antibody specificities in four patients with this allele. STUDY DESIGN AND METHODS: Hemagglutination tests, DNA extraction, polymerase chain reaction (PCR)-restriction fragment length polymorphism, allele-specific PCR, reticulocyte RNA isolation, reverse transcription-PCR cDNA analyses, cloning, and sequencing were performed by standard procedures.
RESULTS: Red blood cells (RBCs) from two patients typed D+C-E-c+e+/-, hrS-/+W, hrB- and their serum was reactive (3+) with all RBC samples of common Rh phenotype tested, but nonreactive with Rhnull or D-- RBCs (apparent alloanti-Rh17). At the RHCE locus, Patient 1 was homozygous for RHCE*ceCF, and Patient 2 inherited RHCE*ceCF in trans to a silenced RHCE*cE. Cross-testing of serum and RBCs from these two samples showed mutual compatibility, indicating that both antibodies define the same novel high-prevalence antigen on Rhce. Two additional patients, one whose serum contained alloanti-c but the RBCs typed C+c+ and one whose serum contained anti-e but the RBCs typed E+e+, also had RHCE*ceCF. RHCE*Ce was present in trans in the former and RHCE*cE in the latter patient.
CONCLUSION: We report that amino acid changes on RhceCF (Trp16Cys, Gln233Glu, and Leu245Val) alter the protein to the extent that c and e antigens are partial, and a high-prevalence antigen, we have named CELO (provisional ISBT Number 004058; RH58) is not expressed. CELO is antithetical to RH43 (Crawford).
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20609196      PMCID: PMC2953576          DOI: 10.1111/j.1537-2995.2010.02764.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  16 in total

1.  A "NEW" RH ANTIBODY (ANTI-RH 26) WHICH DETECTS A FACTOR USUALLY ACCOMPANYING HR'.

Authors:  D W HUESTIS; M L CATINO; S BUSCH
Journal:  Transfusion       Date:  1964 Nov-Dec       Impact factor: 3.157

2.  Observations on subdivisions of the Rh antigen D.

Authors:  P TIPPETT; R SANGER
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

3.  Molecular basis of the LOCR (Rh55) antigen.

Authors:  Gail Coghlan; Marilyn Moulds; Edward Nylen; Teresa Zelinski
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

4.  International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao report.

Authors:  G Daniels; L Castilho; W A Flegel; A Fletcher; G Garratty; C Levene; C Lomas-Francis; J M Moulds; J J Moulds; M L Olsson; M Overbeeke; J Poole; M E Reid; P Rouger; E van der Schoot; M Scott; P Sistonen; E Smart; J R Storry; Y Tani; L-C Yu; S Wendel; C Westhoff; V Yahalom; T Zelinski
Journal:  Vox Sang       Date:  2009-02       Impact factor: 2.144

Review 5.  The Rh antigen D: partial D antigens and associated low incidence antigens.

Authors:  P Tippett; C Lomas-Francis; M Wallace
Journal:  Vox Sang       Date:  1996       Impact factor: 2.144

6.  Involvement of Gly96 in the formation of the Rh26 epitope.

Authors:  B H Faas; P C Ligthart; C Lomas-Francis; M A Overbeeke; A E von dem Borne; C E van der Schoot
Journal:  Transfusion       Date:  1997 Nov-Dec       Impact factor: 3.157

7.  The RHCE allele ceCF: the molecular basis of Crawford (RH43).

Authors:  Willy A Flegel; Franz F Wagner; Qing Chen; Gloria Schlanser; Tom Frame; Connie M Westhoff; Marilyn K Moulds
Journal:  Transfusion       Date:  2006-08       Impact factor: 3.157

8.  Evidence supporting the requirement for two proline residues for expression of c.

Authors:  C M Westhoff; L E Silberstein; D E Wylie
Journal:  Transfusion       Date:  2000-03       Impact factor: 3.157

9.  Anti-HrB and anti-hrb revisited.

Authors:  Bach-Nga Pham; Thierry Peyrard; Séverine Tourret; Marylise Beolet; Hélène Many; Geneviève Juszczak; Michèle Roussel; Sandrine Kappler-Gratias; Philippe Rouger; Pierre-Yves Le Pennec
Journal:  Transfusion       Date:  2009-07-14       Impact factor: 3.157

10.  Deletion of arginine codon 229 in the Rhce gene alters e and f but not c antigen expression.

Authors:  Y X Chen; J Peng; M Novaretti; M E Reid; C-H Huang
Journal:  Transfusion       Date:  2004-03       Impact factor: 3.157

View more
  10 in total

1.  The low-prevalence Rh antigen STEM (RH49) is encoded by two different RHCE*ce818T alleles that are often in cis to RHD*DOL.

Authors:  Marion E Reid; Christine Halter Hipsky; Kim Hue-Roye; Gail Coghlan; Coral Olsen; Christine Lomas-Francis
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

2.  RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa.

Authors:  Connie M Westhoff; Sunitha Vege; Christine Halter Hipsky; Kim Hue-Roye; Tamara Copeland; Randall W Velliquette; Trina Horn; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2012-07-13       Impact factor: 3.157

3.  Variant RH alleles and Rh immunisation in patients with sickle cell disease.

Authors:  Emilia Sippert; Claudia R Fujita; Debora Machado; Glaucia Guelsin; Ane C Gaspardi; Jordão Pellegrino; Simone Gilli; Sara S T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

4.  A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigen.

Authors:  Kim Hue-Roye; Christine Halter Hipsky; Randall W Velliquette; Akiko Fuchisawa; Christine Lomas-Francis; Carolyn Hoppe; Marion E Reid
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

5.  Clinically relevant RHD-CE genotypes in patients with sickle cell disease and in African Brazilian donors.

Authors:  Ane C Gaspardi; Emília A Sippert; Mayra Dorigan De Macedo; Jordão Pellegrino; Fernando F Costa; Lilian Castilho
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

6.  RHD and RHCE molecular analysis in weak D blood donors and in patients with Rh antibodies against their own corresponding Rh antigen.

Authors:  Thamy C Souza Silva; Bruno R Cruz; Sidneia S Costa; Akemi K Chiba; Melca M O Barros; Dante M Langhi; José O Bordin
Journal:  Blood Transfus       Date:  2020-07       Impact factor: 3.443

7.  DIII Type 7 is likely the original serologically defined DIIIb.

Authors:  Christine Lomas-Francis; Christine Halter Hipsky; Randall W Velliquette; Marion E Reid
Journal:  Transfusion       Date:  2011-07-11       Impact factor: 3.157

8.  International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report.

Authors:  J R Storry; L Castilho; G Daniels; W A Flegel; G Garratty; C L Francis; J M Moulds; J J Moulds; M L Olsson; J Poole; M E Reid; P Rouger; E van der Schoot; M Scott; E Smart; Y Tani; L-C Yu; S Wendel; C Westhoff; V Yahalom; T Zelinski
Journal:  Vox Sang       Date:  2011-03-14       Impact factor: 2.144

Review 9.  Genotyping in Sickle Cell Disease Patients: The French Strategy.

Authors:  Aline Floch; Christophe Tournamille; Btissam Chami; France Pirenne
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

10.  RHCE*ceMO is frequently in cis to RHD*DAU0 and encodes a hr(S) -, hr(B) -, RH:-61 phenotype in black persons: clinical significance.

Authors:  Connie M Westhoff; Sunitha Vege; Trina Horn; Kim Hue-Roye; Christine Halter Hipsky; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2013-06-17       Impact factor: 3.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.